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Abstract
Objectives: To determine the cancer incidence in Gipuzkoa
(Spain) from 1998 to 2002 and describe time trends since 1986.
Methods: The annual incidence of cancer in Gipuzkoa from
1998 to 2002 was estimated as a rate per 100,000 inhabitants.
Incidence trends for the period 1986-2002 were studied for all
cancers and for the main cancer sites using Poisson regres-
sion and Joinpoint regression for prostate tumours.
Results: On average, one in 3 men and one in 5 women would
probably be diagnosed with cancer at some time during their
life (0-74 years). Among men, prostate surpassed lung as the
most frequent cancer site. Among women, breast cancer re-
presented approximately 30% of all cases of cancer (exclu-
ding non-melanoma skin cancers). There was an annual in-
crease in the incidence of cancer of 1.5% (95% CI, 1.1-1.8)
in men and 0.9% (95% CI, 0.5-1.3) in women. The incidence
of prostate cancer in men increased over the study period, and
especially between 1996 and 1999, with an annual increase
of 34.7% (95% CI, 5.9-71.5). The incidence of lung cancer in
women presented an annual increase of 5.2% (95% CI, 3.4-
7.1). In contrast, the incidence of stomach cancer decreased
during the study period.
Conclusions: Cancer incidence in Gipuzkoa increased du-
ring the study period. This increase was particularly marked
in lung cancer and skin melanoma, for which preventive stra-
tegies are fundamental.
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Resumen
Objetivos: Conocer la incidencia de cáncer en Guipúzcoa
entre 1998 y 2002, y su evolución desde 1986.
Métodos: Se realizan estimaciones de incidencia anual del
cáncer en el período 1998-2002, para Guipúzcoa, en tasas
por 100.000 habitantes. Se analiza su evolución entre 1986
y 2002 en el conjunto de localizaciones y en las más frecuentes,
mediante el modelo de regresión de Poisson y el modelo de
regresión Joinpoint en tumores de próstata.
Resultados: Uno de cada 3 varones y una de cada 5 muje-
res de Guipúzcoa tienen la probabilidad de desarrollar cán-
cer a lo largo de su vida (rango, 0-74 años). En varones, el
cáncer de próstata ocupa el primer lugar, seguido del cáncer
de pulmón. En mujeres, el cáncer de mama representa cerca
del 30% del total (excluido el de piel no melanoma). Se ob-
serva un incremento anual de incidencia en varones del 1,5%
(intervalo de confianza [IC] del 95%, 1,1-1,8) y del 0,9% (IC
del 95%, 0,5-1,3) en mujeres. Aumentan los tumores de prós-
tata en varones, especialmente en el período 1996-1999 en
un 34,7% anual (IC del 95%, 5,9-71,5), y el cáncer de pul-
món en las mujeres en un 5,2% anual (IC del 95%, 3,4-7,1),
mientras que los tumores de estómago descienden en el pe-
ríodo de estudio
Conclusiones: La incidencia de cáncer en Guipúzcoa aumenta
en el período de estudio; destacan los tumores de pulmón y
melanoma cutáneo, donde las estrategias preventivas de-
sempeñan un papel primordial.
Palabras clave: Cáncer. Tumores malignos. Incidencia. Ten-
dencia.
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Introduction
C
ancer is one of the most important public health
problems in our community, as in other regions.
It has enormous health and socio-economic im-
plications and constitutes the most frequent cause
of premature and avoidable death. In Gipuzkoa 1,600
people die of cancer every year and 3,000 new neo-
plasms are diagnosed. Cancer is identified as one of
the priority health problems within the scope of the Eus-
kadi Health Plan1.
It is also known that the incidence of different types
of cancer varies from one country to another, depen-
ding on etiological factors and also on the availability
of efficient methods of prevention, diagnosis and treat-
ment2. Obtaining the most accurate data possible re-
lating to these aspects therefore constitutes the first step
towards appropriately planning prevention programs and
assigning the health resources required to achieve more
efficient results, in accordance with the scientific evidence
available at any given time.
Population based cancer registry is an essential part
of any rational program of cancer control3. Its primary
function is to keep a file or register of all cases occu-
rring in a defined population. The registry analyses and
interprets such data periodically and provides informa-
tion on the epidemiology of cancer. The value of a can-
cer registry depends on the quality of its data and the
extent to which they are used in research and health
service planning4. Quality control carried out at the local
level for each of the registries is undoubtedly reinfor-
ced by international collaboration5-9.
The aim of this study was to provide insights into the
epidemiology of invasive cancer in Gipuzkoa by analy-
zing population based incidence and time trends, with
special emphasis on sex and site-specific changes over
time.
Methods
The study of cancer incidence included all invasive
neoplasms (except epidermoid and basocellular skin tu-
mours) diagnosed in residents of Gipuzkoa during the
period 1998-2002. According to the 2001 census, this
population numbered 673,563 (330,454 men and
343,109 women). The period was extended to 1986-2002
to analyse time trends. Population estimates in the de-
nominator for calculation of incidence rates were obtained
from the Basque Institute of Statistics.
The main sources of information for the population
cancer registry were the 2 hospital cancer registries avai-
lable in Gipuzkoa (Hospital Donostia and Instituto On-
cológico). These institutions actively search for cases
in the Pathological Anatomy (biopsies, cytologies and
autopsies) and Clinical Documentation (hospital dis-
charges) services, and also in other services. Similar
data were actively collected and compiled at other pu-
blic, concerted and private hospitals in Gipuzkoa.
Death certificates (DC) were also consulted. Finally,
cases were regularly obtained from the cancer regis-
tries of neighbouring communities.
The use of multiple sources makes it possible for the
same case to be received more than once, so data were
cross-checked in order to avoid duplication. Duplication,
processing and concordance control were duly carried
out in all cases identified as being new to the registry.
The automatic quality control program IARC-CHECK10
was used as the final tool for controlling the quality of
the data processed.
The variables used in the study were: a) personal
data: gender and age; b) tumour data: anatomical site
of the primary tumour and its morphology, codified ac-
cording to the 2nd edition of the International Classifi-
cation of Diseases for Oncology (ICD-O-II)11, and date
of diagnosis or incidence, and c) quality indicators: diag-
nostic basis, indicating the most valid basis for diagnosis
and grouped into 2 categories, non-microscopic (clini-
cal, clinical research, surgery and tumour markers) and
microscopic (cytology, histology and autopsy). Cases
whose only source of information was the DC were as-
signed to a separate category.
Data analysis
The average annual incidence of cancer in Gipuz-
koa for the period 1998-2002 is presented for all sites
together, and also for specific sites, and expressed in
rates per 100,000 persons at risk per year. Crude, age-
specific and age-standardized incidence rates were cal-
culated by gender, using the direct method and adjus-
ted with European and World population data3.
Furthermore, cumulative incidence rates were calculated
for each site and gender, from birth to 65 and 75 years
of age.
The cancer incidence trend for the period 1986-2002
was studied for all tumours and the most frequent sites.
The general trend was quantified by applying the Pois-
son regression12, after adjusting for age, with separate
models for men and women. In this model, a linear trend
was assumed for the logarithm of the rates. Goodness
of fit was assessed by deviance and its degrees of free-
dom. The significance level was set at 0.05. In the case
of prostate cancer, the Poisson model did not fit corre-
lated as a result of changes in the trend during the study
period. This was related to the generalised use of pros-
tatic specific antigen (PSA) during the final 5-year pe-
riod. A joinpoint regression model was therefore used
to analyse the time-related trends for these tumours. This
made it possible to estimate annual percentage chan-
ge (APC) and to identify trend inflexion points when they
were present13. For data analysis, we used version 9.1
of the SAS statistical package14 and version 3.0 of the
Joinpoint Regression program15.
Results
The number of neoplasms registered in Gipuzkoa
between the years 1998 and 2002 was 16,329, of which
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9,991 were diagnosed in men and 6,338 in women. This
meant a crude annual incidence rate, for the period 1998-
2002, of 604.2 per 100,000 male inhabitants and
369.1 per 100,000 females. 
During this 5-year period, 61% of the cancers re-
gistered in men and 54% of those in women were diag-
nosed in people over 65 years of age, with 26% and
32%, respectively, being diagnosed in men and women
over 75 years of age. The cumulative rates for ages 0
to 64 were found to be 18.8% in men and 13.3% in
women and those for ages 0 to 74 were, 42.0% in men
and 21.3% in women.
The incidence of cancer increased with age; rates
were very similar for men and women until 20 years
of age, but between 20 and 45 rates in females were
higher than those in males. However, from this age
on, there was a gradual increase in the incidence for
both groups, with a more marked increase for men
(fig. 1).
The mean age at diagnosis for the whole period was
65.5, with it greater for men (66.1 years) than for women
(64.8 years). This was mainly due to the fact that ave-
rage age at the appearance of breast tumours (60.3
years), the most frequent cancer in women, was lower
than that of prostate tumours (71.4 years), the most com-
mon type of cancer in men. However, for the most fre-
quent tumours common to both sexes, age at appea-
rance was greater in women. This was the case of
tumours located in the stomach (men 68.6, women 73.3),
colon-rectum (men 68.3 and women 70.4), bladder (men
67.1, women 71.8) and oral cavity and pharynx (men
60.1 and women 63.0).
During the study period, the prostate (22.9%) was
the most frequently affected site in men, followed by the
tracheal-bronchial-lung (C33-C34: 14.6%) and colon-rec-
tum (C18-C20: 12.6%) (table 1). Breast cancer (27.9%)
was the most frequent neoplasm in women, followed by
colorectal cancer (C18-C20: 13.4%) and cancer of the
uterus (C53-C55: 8.7%) (table 2).
In general, neoplasms were more frequent in men
than in women for all sites except thyroids and skin me-
lanomas. The age-standardized rate ratio between men
and women for all sites was 2.7, and the sites with the
highest rate ratios were the larynx (19.1), oesophagus
(7.2), tracheal-bronchial-lung (7.2), urinary bladder
(6.9) and lip-oral cavity and pharynx (4.9).
Between the years 1986 and 2002, the incidence of
cancer in Gipuzkoa underwent an annual increase of
1.46% (95% confidence interval CI, 1.14-1.77) in men
and 0.91% (95% CI, 0.53-1.30) in women. Trends for
the most frequent sites are shown in table 3. In men,
the tumour site with the greatest increase during the
study period was the prostate. This increase was not
linear. It is possible to distinguish 3 well-differentiated
periods: 1986-1996, with an APC of 2.9% (95% CI, 0.1-
5.8); 1996-1999, with an annual increase of 34.7% (95%
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Figure 1. Cancer incidence in Gipuzkoa (1998-2002) by age group and sex.
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Table 1. Cancer incidence in males in Gipuzkoa (1998-2002)
Cases Rate per 100,000 Cumulative rate (%)
ICD-O-II Topography n Percentage Crude ASR(E) ASR(W) 0-64 0-74
C00 Lip 56 0.56 3.39 2.82 1.92 0.26 0.09
C01-C02 Tongue 96 0.96 5.81 5.17 3.72 0.47 0.26
C03-C06 Mouth 92 0.92 5.56 5.00 3.77 0.46 0.27
C07-C08 Salivary glands 24 0.24 1.45 1.28 0.91 0.07 0.06
C09 Tonsils 33 0.33 2.00 1.82 1.35 0.16 0.12
C10 Other oropharynx 34 0.34 2.06 1.90 1.38 0.16 0.12
C11 Nasopharynx 27 0.27 1.63 1.49 1.13 0.14 0.10
C12-C13 Hypopharynx 93 0.93 5.62 5.12 3.75 0.43 0.31
C14 Unspecified pharynx 47 0.47 2.84 2.59 1.94 0.20 0.15
C15 Oesophagus 220 2.19 13.31 11.77 8.23 0.93 0.58
C16 Stomach 543 5.41 32.84 27.54 18.29 2.22 0.88
C17 Intestine 11 0.11 0.67 0.58 0.41 0.04 0.03
C18 Colon 761 7.59 46.02 38.21 25.32 3.03 1.15
C19-C20 Rectum 495 4.93 29.94 25.26 17.09 2.14 0.93
C21 Anus 10 0.10 0.61 0.51 0.37 0.03 0.02
C22 Liver 267 2.66 16.15 13.61 9.43 1.23 0.46
C23-C24 Gall bladder and bile duct 75 0.75 4.54 3.78 2.34 0.22 0.08
C25 Pancreas 222 2.21 13.43 11.46 7.92 0.95 0.46
C30-C31 Nose, sinuses and ear 30 0.30 1.81 1.55 1.12 0.14 0.07
C32 Larynx 343 3.42 20.74 18.38 13.33 1.63 0.96
C33-C34 Trachea, bronchus and lung 1,461 14.56 88.36 74.97 51.54 6.25 2.91
C37-C38 Other thoracic organs 12 0.12 0.73 0.61 0.47 0.06 0.03
C40-C41 Bone 27 0.27 1.63 1.80 1.91 0.15 0.13
C43 Skin melanoma 133 1.33 8.04 7.15 5.41 0.59 0.38
C45 Mesothelioma 20 0.20 1.21 1.02 0.69 0.09 0.04
C46 Kaposi sarcoma 14 0.14 0.85 0.74 0.54 0.05 0.05
C47+C49 Connective and soft tissues 53 0.53 3.21 2.87 2.20 0.21 0.15
C50 Breast 26 0.26 1.57 1.36 0.89 0.10 0.05
C60 Penis 23 0.23 1.39 1.18 0.78 0.10 0.03
C61 Prostate 2,293 22.86 138.67 111.68 72.20 9.30 2.43
C62 Testicle 61 0.61 3.69 3.23 3.13 0.23 0.23
C63 Other male genital organs 3 0.03 0.18 0.16 0.10 0.01 0.00
C64 Kidney 323 3.22 19.53 16.82 11.68 1.35 0.73
C65 Pelvis renal 34 0.34 2.06 1.69 1.16 0.15 0.05
C66 Ureter 14 0.14 0.85 0.67 0.45 0.05 0.02
C67 Bladder 766 7.64 46.32 39.11 26.45 3.02 1.43
C68 Other urinary organs 1 0.01 0.06 0.05 0.04 0.01 0.00
C69 Eye 9 0.09 0.54 0.53 0.47 0.05 0.03
C70-C72 Brain, nervous system 177 1.76 10.70 9.76 7.62 0.82 0.56
C73 Thyroid 47 0.47 2.84 2.55 2.18 0.20 0.16
C74 Adrenal gland 8 0.08 0.48 0.40 0.30 0.03 0.02
C75 Other endocrine glands 2 0.02 0.12 0.10 0.12 0.01 0.01
C81 Hodgkin lymphoma 69 0.69 4.17 3.93 3.80 0.30 0.27
C82-85, C96 Non-Hodgkin lymphoma 289 2.88 17.48 15.43 11.62 1.24 0.76
C88 Immunoproliferative diseases 4 0.04 0.24 0.18 0.12 0.02 0.00
C90 Multiple myeloma 89 0.89 5.38 4.42 2.96 0.35 0.14
C91 Lymphoid leukaemia 97 0.97 5.87 5.50 4.49 0.40 0.22
C92-C94 Myeloid leukemia 43 0.43 2.60 2.25 1.69 0.17 0.09
C95 Unspecified leukemia 58 0.58 3.51 2.97 2.12 0.24 0.10
O&U Other and poorly defined 396 3.95 23.95 20.15 13.42 1.49 0.63
C00-O&U All sites 10,031 100.00 606.63 513.10 354.26 41.96 18.75
ASR(E): age-standardized rates (European population); ASR(W): age-standardized rates (world population).
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Table 2. Cancer incidence in women Gipuzkoa (1998-2002)
Cases Rate per 100,000 Cumulative rates (%)
ICD-O-II Topography n Percentage Crude ASR(E) ASR(W) 0-64 0-74
C00 Lip 12 0.19 0.70 0.38 0.25 0.04 0.00
C01-C02 Tongue 34 0.53 1.98 1.54 1.17 0.15 0.06
C03-C06 Mouth 29 0.46 1.69 1.15 0.80 0.09 0.05
C07-C08 Salivary glands 19 0.30 1.11 0.88 0.71 0.07 0.05
C09 Tonsils 5 0.08 0.29 0.25 0.21 0.02 0.02
C10 Other oropharynx 1 0.02 0.06 0.06 0.04 0.00 0.00
C11 Nasopharynx 7 0.11 0.41 0.35 0.26 0.03 0.02
C12-C13 Hypopharynx 5 0.08 0.29 0.27 0.21 0.02 0.02
C14 Unspecified pharynx 12 0.19 0.70 0.61 0.44 0.05 0.04
C15 Oesophagus 44 0.69 2.56 1.70 1.14 0.10 0.07
C16 Stomach 267 4.19 15.55 9.34 6.19 0.70 0.27
C17 Intestine 9 0.14 0.52 0.33 0.22 0.03 0.01
C18 Colon 585 9.19 34.07 21.89 14.71 1.67 0.79
C19-C20 Rectum 263 4.13 15.32 10.35 6.98 0.82 0.40
C21 Anus 15 0.24 0.87 0.61 0.41 0.04 0.02
C22 Liver 111 1.74 6.47 3.72 2.43 0.29 0.08
C23-C24 Gall bladder and bile duct 124 1.95 7.22 4.33 2.83 0.32 0.13
C25 Pancreas 207 3.25 12.06 7.33 4.82 0.55 0.23
C30-C31 Nose, sinuses and ear 9 0.14 0.52 0.46 0.42 0.03 0.03
C32 Larynx 19 0.30 1.11 0.91 0.70 0.08 0.05
C33-C34 Trachea, bronchus and lung 232 3.64 13.51 9.95 7.15 0.77 0.47
C37-C38 Other thoracic organs 8 0.13 0.47 0.42 0.39 0.03 0.02
C40-C41 Bone 15 0.24 0.87 0.77 0.67 0.05 0.05
C43 Skin melanoma 209 3.28 12.17 10.06 7.90 0.79 0.60
C45 Mesothelioma 9 0.14 0.52 0.41 0.31 0.04 0.02
C46 Kaposi sarcoma 5 0.08 0.29 0.15 0.09 0.01 0.00
C47+C49 Connective and soft tissues 43 0.68 2.51 2.19 2.01 0.17 0.12
C50 Breast 1,778 27.92 103.56 84.81 62.91 6.75 5.05
C51 Vulva 53 0.83 3.09 1.79 1.16 0.10 0.06
C52 Vagina 8 0.13 0.47 0.41 0.33 0.03 0.02
C53 Cervix uteri 120 1.88 6.99 5.92 4.54 0.49 0.34
C54 Corpus uteri 410 6.44 23.88 18.32 12.95 1.60 0.93
C55 Uterus unspecified 20 0.31 1.17 0.77 0.52 0.04 0.04
C56 Ovary 232 3.64 13.51 10.87 8.28 0.88 0.62
C57 Other female genital organs 9 0.14 0.52 0.40 0.28 0.03 0.02
C64 Kidney 136 2.14 7.92 5.67 4.17 0.44 0.23
C65 Renal pelvis 5 0.08 0.29 0.17 0.11 0.02 0.00
C66 Ureter 3 0.05 0.18 0.15 0.12 0.02 0.01
C67 Bladder 157 2.47 9.14 5.65 3.81 0.42 0.19
C69 Eye 12 0.19 0.70 0.58 0.50 0.04 0.03
C70-C72 Brain, nervous system 167 2.62 9.73 7.04 5.30 0.52 0.34
C73 Thyroids 127 1.99 7.40 6.54 5.41 0.53 0.42
C74 Adrenal gland 12 0.19 0.70 0.67 0.62 0.04 0.04
C81 Hodgkin lymphoma 44 0.69 2.56 2.46 2.44 0.00 0.00
C82-85, C96 Non-Hodgkin lymphoma 260 4.08 15.14 10.90 8.16 0.19 0.17
C88 Immunoproliferative disease 1 0.02 0.06 0.02 0.01 0.87 0.50
C90 Multiple myeloma 84 1.32 4.89 3.11 2.07 0.26 0.10
C91 Lymphoid leukemia 54 0.85 3.15 2.45 2.10 0.21 0.11
C92-C94 Myeloid leukemia 23 0.36 1.34 1.03 0.85 0.08 0.05
C95 Unspecified leukemia 57 0.89 3.32 2.33 1.82 0.16 0.10
O&U Other land poorly defined 299 4.69 17.42 9.73 6.24 0.59 0.26
C00-O&U All sites 6,369 100.00 370.96 272.16 198.14 21.27 13.26
ASR(E): age-standardized rates (European population); ASR(W): age-standardized rates (world population).
CI, 5.9-71.5); and 1999-2002, in which no significant
changes were observed (fig. 2). After prostate cancer,
the tumours with the greatest APC in men were: thy-
roid (5.6%), skin melanoma (4.6%), kidney (2.8%) and
colon-rectum (2.6%) cancer. Significant decreases
were observed in stomach (2.8%), oesophagus (2.5%)
and lip-oral cavity-pharynx (2.1%) cancer. No significant
changes were observed in the incidence of tracheal-bron-
chial-lung and bladder urinary tumours. In women, the
greatest annual increase occurred in tracheal-bronchial-
lung tumours (5.2%), followed by skin melanoma
(4.6%) and thyroid (4.0%) cancer. Significant decrea-
ses were observed in stomach tumours (4.4%) and in
gallbladder and bile duct tumours (2.3%). No significant
changes were observed in tumours of the cervix,
ovary and urinary bladder.
The quality indicators used showed a high degree
of exhaustiveness and highlighted the good quality of
the data compiled. Over the whole period, there were
only 5 cases in which the age and date of birth were
unknown at the moment of diagnosis, and none in the
last five-year period. The percentage of cases with his-
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Table 3. Cancer incidence in Gipuzkoa (1986-2002): rates (per 100,000) and time trends (Poisson regression)
Males
ICD-O-II Topography ASR(W) 1986 (95%CI) ASR(W) 2002 (95%CI) APC (95%CI) Deviance
C00-C14 Oropharynx 27.5 (22.28 to 32.64) 17.2 (13.55 to 20.83) –2.1 (–2.99 to –1.28) 0.8447
C15 Oesophagus 10.5 (7.30 to 13.67) 9.0 (6.40 to 11.66) –2.5 (–3.84 to –1.08) 1.0450
C16 Stomach 28.1 (22.92 to 33.34) 16.2 (12.86 to 19.45) –2.8 (–3.68 to –1.83) 1.0700
C18-C20 Colon-rectum 29.8 (24.43 to 35.20) 46.2 (40.55 to 51.92) 2.6 (1.73 to 3.41) 1.3294
C22 Liver 7.0 (4.35 to 9.60) 9.1 (6.50 to 11.66) 1.3 (–0.24 to 2.79) 1.0190
C23-C24 Gall bladder and bile duct 0.6 (–0.09 to 1.29) 2.3 (1.03 to 3.49) –0.7 (–3.32 to 2.00) 1.1486
C25 Pancreas 6.0 (3.56 to 8.34) 9.4 (6.75 to 12.09) 0.4 (–1.30 to 2.21) 1.1653
C32 Larynx 20.8 (16.33 to 25.21) 14.3 (11.01 to 17.63) –1.8 (–3.02 to –0.63) 1.1370
C33-C34 Trachea, bronchus, lung 49.0 (42.12 to 55.86) 52.2 (46.06 to 58.33) 0.4 (–0.28 to 1.02) 1.1139
C43 Skin melanoma 2.1 (0.63 to 3.57) 5.3 (3.25 to 7.35) 4.6 (2.07 to 7.20) 1.1078
C61 Prostate 16.4 (12.41 to 20.33) 78.3 (71.15 to 85.42) 2.8999a
C67 Bladder 23.0 (18.32 to 27.67) 25.0 (20.84 to 29.20) 0.2 (–0.72 to 1.09) 1.1416
C64–C66 Kidney and ureter 7.7 (4.80 to 10.62) 13.2 (10.09 to 16.23) 2.9 (1.48 to 4.23) 1.0207
C73 Thyroids 1.0 (–0.11 to 1.54) 2.4 (0.89 to 3.87) 5.6 (1.76 to 9.59) 0.9370
C91-C95 Leukemias 8.7 (5.52 to 11.93) 8.4 (5.08 to 11.67) –0.4 (–2.02 to 1.33) 1.0614
O&U Other and poorly defined 18.9 (14.56 to 23.19) 12.0 (9.08 to 14.84) –2.2 (–3.32 to –1.09) 1.0549
Females
ICD-O-II Topography ASR(w) 1986 (95%CI) ASR(w) 2002 (95%CI) ASR(w) (95%CI) Deviance
C00-C14 Oropharynx 2.4 (1.07 to 3.84) 3.6 (1.61 to 5.65) 2.5 (0.13 to 4.93) 1.0525
C15 Oesophagus 0.6 (–0.03 to 1.32) 1.4 (0.39 to 2.45) 3.5 (–0.64 to 7.76) 0.9194
C16 Stomach 10.4 (7.67 to 13.23) 6.0 (4 to 8.04) –4.4 (–5.67 to –3.10) 1.0881
C18-C20 Colon-rectum 14.7 (11.46 to 17.83) 20.4 (16.83 to 23.93) 1.5 (0.64 to 2.37) 1.0187
C22 Liver 1.8 (0.65 to 3.03) 3.0 (1.56 to 4.48) 3.2 (0.89 to 5.57) 0.8463
C23-C24 Gall bladder and bile duct 4.8 (2.99 to 6.62) 1.98 (1.01 to 2.94) 2.3 (–4.09 to –0.38) 0.9046
C25 Pancreas 3.1 (1.81 to 4.39) 4.8 (3.12 to 6.47) 1.0 (–0.72 to 2.81) 1.0568
C33-C34 Trachea, bronchus, lung 4.0 (2.24 to 5.79) 7.9 (5.47 to 10.25) 5.2 (3.36 to 7.05) 0.9540
C43 Skin melanoma 3.1 (1.49 to 4.81) 7.5 (4.81 to 10.19) 4.6 (2.59 to 6.67) 1.1709
C50 Breast 44.8 (38.39 to 51.13) 57.5 (50.84 to 64.06) 1.5 (0.79 to 2.24) 1.5815
C53 Cervix 3.1 (1.47 to 4.78) 3.6 (1.97 to 5.24) –0.5 (–2.60 to 1.60) 1.0527
C54 Uterine corpus 9.7 (6.90 to 12.54) 12.1 (9.17 to 15.09) 2.8 (1.54 to 4.01) 0.9829
C56 Ovary 9.1 (6.22 to 11.97) 7.2 (4.49 to 9.88) –1.0 (–2.49 to 0.45) 1.0459
C67 Bladder 2.5 (1.23 to 3.84) 3.4 (2.06 to 4.81) –0.5 (–1.44 to 2.45) 0.9718
C64-C66 Kidney and ureter 1.9 (0.68 to 3.20) 4.5 (2.29 to 6.73) 1.6 (–0.13 to 3.44) 0.7795
C73 Thyroids 2.2 (0.76 to 3.73) 8.0 (5.24 to 10.69) 4.0 (1.67 to 6.46) 1.1146
C91-C95 Leukemias 3.4 (1.32 to 5.50) 5.0 (2.20 to 7.72) 0.2 (–1.89 to 2.23) 1.1206
O&U Other and poorly defined 14.2 (11.09 to 17.30) 4.7 (3.10 to 6.39) –3.9 (–5.25 to –2.60) 1.1325
aBad fit.
ASR(W): age-standardized rates (world population); APC: annual percentage change; CI: confidence interval.
tological verification was almost 90% for the last five-
year period, while during the same period the propor-
tion of cases with unknown or poorly defined primary
sites was less than 5%, with an annual decrease of 2.2%
in men and 3.9% in women over the study period (table
3). Finally, cases in which the only source of data was
the death certificate (DCO) accounted for less than 2.5%
of the total in the last few years.
Discussion
The average annual frequency of appearance of new
cases of cancer in Gipuzkoa between 1998 and 2002
was 607/100,000 for men and 371/100,000 for women,
with a standardized man/woman rate ratio of 2.7 and
an average age at diagnosis of 66 years for men and
64 for women.
Data published from the Spanish cancer registries16-18
shows a north-south gradient in men, with higher inci-
dence rates in the north of Spain, in contrast to women
with similar rates in Navarra, the Basque Country and
Tarragona, and somewhat lower rates in Granada and
Zaragoza19. In periods prior to 1998, incidence rates for
cancer in women resident in Gipuzkoa, as for those for
women from other regions of Spain, were amongst the
lowest in Europe, while those for men were similar to
the European average.
The pattern of cancer in men from Gipuzkoa for the
last 5-year period studied shows a high incidence of to-
bacco and alcohol related tumours (lip, oral cavity,
pharynx, larynx, oesophagus and lung). Similar rates
were observed in previous periods for this region and
also for the whole of Spain20. Lung cancer, which was
the most frequent neoplasm in males in previous pe-
riods, descended to second place, mainly due to the sig-
nificant increase in prostate tumours. In women, inci-
dence data for the five-year period 1998-2002 show a
similar pattern to those of previous periods, with a gra-
dual increase in the rates of the most frequent tumours:
breast and colon-rectum tumours, and also in cancers
of the uterus. Malignant breast cancers represented 28%
of all cancers (excluding non-melanoma skin cancer)
and followed the same upward trend observed in other
regions of Spain and countries worldwide21-23. 
In general, a progressive increase in the number of
cancer cases was observed during the study period 
in both men and women. The overall annual increa-
ses in the incidence of cancer were 1.5% in men and
0.9% in women. This overall increase in the detection
of tumours corresponds to general trends for the most
frequent tumours in both men and women. The ex-
ceptions to the rule were stomach tumours, which de-
creased in both sexes, and tumours of the oral cavity
and pharynx and oesophagus, which decreased in men.
In men, the great increase observed in prostate can-
cer, with an annual increase of 2.9% in the period 1986-
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Figure 2. Age-standardized incidence trends of prostate cancer in Gipuzkoa (1986-2002).
APC: annual percent change; CI: confidence interval.
1996, and a very sharp annual increase (34.7%) bet-
ween 1996 and 1999, reflects the increase in diagno-
sis related to the widespread use of the PSA test. Re-
gistered cases of prostate cancer have been on the
increase in France since 1985 and in Spain since 199024.
Nevertheless, in the data presented here, the observed
increase was 100% in 3 years, while increases in de-
tection associated with the use of PSA in other coun-
tries, in earlier periods, were more gradual25,26. On the
other hand, the incidence of lung cancer stabilized, but
the decrease described in some other European coun-
tries and in the USA was not observed27,28. In some Eu-
ropean countries, the incidence of lung cancer in men
has decreased since the 1980’s, while in southern Eu-
rope it continued to increase until the 1990’s, with a pat-
tern reflecting the epidemic of tobacco smoking affec-
ting certain regions29. The number of male smokers in
some northern European countries began to descend
in the 1960’s. Nevertheless, in some southern European
countries, including Spain, this decrease in male tobacco
consumption did not begin until the 1980’s30.
In women, although the increases in breast and
colon-rectum cancers were greater, in absolute num-
bers, than those observed for other tumours, the gre-
atest percentage increases were observed for tumours
such us lung cancer (5.2% annually). Although the in-
cidence rates of these tumours are still much lower than
for men, they are now increasing, as previously occu-
rred in other western nations25,27,31. Tobacco consump-
tion by Spanish women increased rapidly from 1970 on-
wards and continued to increase until the 1990’s31. This
implied a lag of 20-40 years compared to the experience
of women in other western countries and this will also
be reflected in the evolution of the incidence of tobac-
co-related cancers32. 
The incidence of melanoma in Gipuzkoa showed an
annual increase of 4.6% in both men and women. The
incidence of these tumours in Europe has been rising
steadily, albeit with differences between countries33-35,
though a deceleration in the general trend has been
observed in northern Europe36. This general increase
has been associated with exposure to ultraviolet ra-
diation in combination with endogenous factors such
as skin type and genetic predisposition37. Finally, the
increase in the incidence of thyroid cancer, particularly
in women (4%), has also been described by other aut-
hors, as has a decline in mortality rates38,39. This indi-
cates that the observed increase may be due to im-
proved diagnosis and to the identification of a greater
number of small, well-differentiated, tumours. Exposure
to radiation and other substances that affect the thy-
roid function are amongst the etiological factors40, thus
this type of tumour showed a greater incidence in areas
of endemic goitre.
For the last period studied, the quality indicators of
the cancer register support both the validity and the ex-
haustiveness of the cancer registry, confirming the qua-
lity of the data presented. In addition, the decrease ob-
served in the number of tumours with poorly defined sites
was clearly related to improvements in the quality of diag-
nostic data. An age-period-cohort analysis for specific
sites would provide more detailed data about factors that
could possibly explain the increase in the incidence of
cancer. In Spain, pronounced cohort effects have been
described for lung41 and breast21 cancer, amongst ot-
hers, indicating respective changes in the prevalence
of risk factors such as tobacco and reproductive aspects,
in specific birth-defined cohorts. In the case of prosta-
te cancer, the period considered and the generalized
use of PSA seems to have had a greater effect on the
changes observed, which affected all age groups. Even
so, significant cohort effects have also been described
suggesting the influence of etiological factors42.
In conclusion, the study data reflect an important rise
in the incidence of neoplasms in Gipuzkoa in most sites,
and most notably in those associated with preventable
risk factors, as is the case of lung tumours in women
and skin melanoma in both sexes.
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